BioRay Pharmaceutical

Taizhou, China Founded: 2019 • Age: 7 yrs Acquired By PAG
Antibody therapeutics for immunology and oncology are developed.
Request Access

About BioRay Pharmaceutical

BioRay Pharmaceutical is a company based in Taizhou (China) founded in 2019 was acquired by PAG in September 2019.. BioRay Pharmaceutical has raised $214.97 million across 1 funding round from investors including PAG. BioRay Pharmaceutical operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Horizon Therapeutics and Forge Biologics, among others.

  • Headquarter Taizhou, China
  • Stage Unicorn
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Bioray Pharmaceutical Corp
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $214.97 M (USD)

    in 1 rounds

  • Latest Funding Round
    $214.97 M (USD), Series D

    Dec 29, 2022

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    PAG

    (Sep 05, 2019)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of BioRay Pharmaceutical
Headcount 1000-5000
Employee Profiles 4
Employee Profiles
People
Zhenwu Luo
Senior Scientist

Unlock access to complete

Teams

Unlock access to complete

Funding Insights of BioRay Pharmaceutical

BioRay Pharmaceutical has successfully raised a total of $214.97M through 1 strategic funding round. The most recent funding activity was a Series D round of $214.97 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series D — $215.0M
  • First Round

    (29 Dec 2022)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2022 Amount Series D - BioRay Pharmaceutical Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in BioRay Pharmaceutical

BioRay Pharmaceutical has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include PAG. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Alternative investment firm
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by BioRay Pharmaceutical

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - BioRay Pharmaceutical

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Bioray Pharmaceutical Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of BioRay Pharmaceutical

BioRay Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Horizon Therapeutics and Forge Biologics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
domain founded_year HQ Location
Developer of drugs for treating rare and autoimmune diseases
domain founded_year HQ Location
Gene therapies for rare diseases are developed to treat patients.
domain founded_year HQ Location
Therapeutic antibodies for cancer and other diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about BioRay Pharmaceutical

When was BioRay Pharmaceutical founded?

BioRay Pharmaceutical was founded in 2019 and raised its 1st funding round 3 years after it was founded.

Where is BioRay Pharmaceutical located?

BioRay Pharmaceutical is headquartered in Taizhou, China. It is registered at Taizhou, Jiangsu, China.

Who is the current CEO of BioRay Pharmaceutical?

Haibin Wang is the current CEO of BioRay Pharmaceutical.

Is BioRay Pharmaceutical a funded company?

BioRay Pharmaceutical is a funded company, having raised a total of $214.97M across 1 funding round to date. The company's 1st funding round was a Series D of $214.97M, raised on Dec 29, 2022.

What does BioRay Pharmaceutical do?

BioRay Pharmaceutical was founded in 2019 in Taizhou, China, within the biotechnology sector. Therapeutics are developed using an antibody-technology platform targeted at immune-mediated diseases, including rheumatoid arthritis, psoriasis, and Ankylosing Spondylitis. Drugs for cancer and tumors are also offered. Formulated products derived from organic ingredients are provided to support health restoration and bodily balance. Operations focus on immunology and oncology research and development.

Who are the top competitors of BioRay Pharmaceutical?

BioRay Pharmaceutical's top competitors include Moderna, argenx and BeiGene.

Who are BioRay Pharmaceutical's investors?

BioRay Pharmaceutical has 1 investor. Key investors include PAG.

What is BioRay Pharmaceutical's valuation?

The valuation of BioRay Pharmaceutical is $1.9B as of Dec 2022.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available